This trial aims to investigate the relative bioavailability of three different oral formulations of BI 764198 and how this is influenced by food.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
BI 764198, formulation 1
BI 764198, formulation 2
BI 764198, formulation 3
Humanpharmakologisches Zentrum Biberach
Biberach/Riss, Germany
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Time frame: up to 4 days
Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: up to 4 days
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: up to 4 days
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point, dose normalized (AUC0-tz, norm)
Time frame: up to 4 days
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity, dose normalized (AUC0-∞, norm)
Time frame: up to 4 days
Maximum measured concentration of the analyte in plasma, dose normalised (Cmax, norm)
Time frame: up to 4 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.